Profile of infliximab in the treatment of pediatric Crohn’s disease

References

• FoodUSAdministrationDrugInfliximab product approval information – licensing action Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm093327.htmAccessed December 29, 2014
   Google Scholar
• CucchiaraSMorley-FletcherA“New drugs: kids come first”: children should be included in trials of new biological treatmentsInflamm Bowel Dis2007131165116917455208
   PubMed Web of Science ®Google Scholar
• RosenbachYHartmanCShapiroRHirschAAvitzurYShamirRAdalimumab treatment in children with refractory Crohn’s diseaseDig Dis Sci20105574775319333754
   PubMed Web of Science ®Google Scholar
• PresentDHRutgeertsPTarganSInfliximab for the treatment of fistulas in patients with Crohn’s diseaseN Engl J Med19993401398140510228190
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med200435087688514985485
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet20023591541154912047962
   PubMed Web of Science ®Google Scholar
• HyamsJCrandallWKugathasanSInduction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in childrenGastroenterology200713286387317324398
   PubMed Web of Science ®Google Scholar
• ParashetteKRMakamRCCuffariCInfliximab therapy in pediatric Crohn’s disease: a reviewClin Exp Gastroenterol20103576321694847
   PubMedGoogle Scholar
• D’HaensGVan DeventerSVan HogezandREndoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trialGastroenterology19991161029103410220494
   PubMed Web of Science ®Google Scholar
• KierkusJDadalskiMSzymanskaEThe impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn’s diseaseEur J Gastroenterol Hepatol20122449550022387887
   PubMed Web of Science ®Google Scholar
• PaulSDel TedescoEMarotteHTherapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective studyInflamm Bowel Dis2013192568257624013361
   PubMed Web of Science ®Google Scholar
• YoshidaKFukunagaKIkeuchiHScheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trialInflamm Bowel Dis2012181617162322081474
   PubMed Web of Science ®Google Scholar
• AmiotASetakhrVSeksikPLong-term outcome of enterocutaneous fistula in patients with Crohn’s disease treated with anti-TNF therapy: a cohort study from the GETAIDAm J Gastroenterol20141091443144925091063
   PubMed Web of Science ®Google Scholar
• HyamsJSLererTGriffithsALong-term outcome of maintenance infliximab therapy in children with Crohn’s diseaseInflamm Bowel Dis20091581682219107783
   PubMed Web of Science ®Google Scholar
• BellSJKammMAReview article: the clinical role of anti-TNFα antibody treatment in Crohn’s diseaseAliment Pharmacol Ther20001450151410792111
   PubMed Web of Science ®Google Scholar
• ReineckerHCSteffenMWitthoeftTEnhanced secretion of tumour necrosis factor-α, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s diseaseClin Exp Immunol1993941741818403503
   PubMed Web of Science ®Google Scholar
• NichollsSStephensSBraeggerCPWalker-SmithJAMacDonaldTTCytokines in stools of children with inflammatory bowel disease or infective diarrhoeaJ Clin Pathol1993467577608408704
   PubMed Web of Science ®Google Scholar
• LugeringASchmidtMLugeringNPauelsHGDomschkeWKucharzikTInfliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathwayGastroenterology20011211145115711677207
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrinhHKnightDMGhrayebJChimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine199572512597640345
   PubMed Web of Science ®Google Scholar
• ten HoveTvan MontfransCPeppelenboschMPvan DeventerSJInfliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s diseaseGut20025020621111788561
   PubMed Web of Science ®Google Scholar
• ChoyEHPanayiGSCytokine pathways and joint inflammation in rheumatoid arthritisN Engl J Med200134490791611259725
   PubMed Web of Science ®Google Scholar
• BuksJWilczakMRzymskiPOpalaTDo soluble p55 and p75 TNF-receptor concentrations play a role in women with primary sterility?Arch Med Sci2010626426922371757
   PubMed Web of Science ®Google Scholar
• GrellMTumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNFJ Inflamm1995478178913925
   PubMedGoogle Scholar
• NaudePJden BoerJALuitenPGEiselLMTumor necrosis factor receptor cross-talkFEBS J201127888889821232019
   PubMed Web of Science ®Google Scholar
• GrellMWajantHZimmermannGScheurichPThe type I receptor (CD 120a) is the high-affinity receptor for soluble tumor necrosis factorProc Natl Acad Sci U S A1998955705759435233
   PubMed Web of Science ®Google Scholar
• KafrouniMIBrownGRThieleDLThe role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infectionJ Leukoc Biol20037456457112960267
   PubMed Web of Science ®Google Scholar
• RuemmeleFMVeresGKolhoKLConsensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s diseaseJ Crohns Colitis201481179120724909831
   PubMed Web of Science ®Google Scholar
• OlbjornCNakstadBSmastuenMCThiis-EvensenEVatnMHPerminowGEarly anti-TNF treatment in pediatric Crohn’s disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patientsScand J Gastroenterol2014491425143125310799
   PubMed Web of Science ®Google Scholar
• SzymanskaEDadalskiMOraczGKierkusJCohort profile: pediatric patients with Crohn’s disease qualified to biologic therapyPost N Med20143162165 Polish
   Google Scholar
• PaulTBirnbaumAPalDKDistinct phenotype of early childhood inflammatory bowel diseaseJ Clin Gastroenterol20064058358616917397
   PubMed Web of Science ®Google Scholar
• CanniotoZBertiIMartelossiSIBD and IBD mimicking enterocolitis in children younger than 2 years of ageEur J Pediatr200916814915518546019
   PubMed Web of Science ®Google Scholar
• Walker-SmithJALebenthalEBranskiDPediatric and Inflammatory Bowel Disease: Perspective and Consequences14Basel, SwitzerlandKarger2014118
   Google Scholar
• HendersonPvan LimbergenJEWilsonDCGenetics of childhood-onset inflammatory bowel diseaseInflamm Bowel Dis20111734636120839313
   PubMed Web of Science ®Google Scholar
• ImielinskiMBaldassanoRNGriffithsACommon variants at five new loci associated with early-onset inflammatory bowel diseaseNat Genet2009411335134019915574
   PubMed Web of Science ®Google Scholar
• GlockerEOKotlarzDBoztugKInflammatory bowel disease and mutations affecting the interleukin-10 receptorN Engl J Med20093612033204519890111
   PubMed Web of Science ®Google Scholar
• KaneSVJaganathanSBedenbaughAVPalmerLSchwartzDAAnti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn’s diseaseCurr Med Res Opin2014301821182624884302
   PubMed Web of Science ®Google Scholar
• MagroFSantos-AntunesJVilas-BoasFCrohn’s disease outcome in patients under azathioprine: a tertiary referral center experienceJ Crohns Colitis2014861762524332869
   PubMed Web of Science ®Google Scholar
• CrandallWHyamsJKugathasanSInfliximab therapy in children with concurrent perianal Crohn disease: observations from REACHJ Pediatr Gastroenterol Nutr20094918319019561542
   PubMed Web of Science ®Google Scholar
• VeresGBaldassanoRNMamulaPInfliximab therapy in children and adolescents with inflammatory bowel diseaseDrugs2007671703172317683171
   PubMed Web of Science ®Google Scholar
• BaldassanoRBraeggerCPEscherJCInfliximab (REMI-CADE) therapy in the treatment of pediatric Crohn’s diseaseAm J Gastroenterol20039883383812738464
   PubMed Web of Science ®Google Scholar
• ChurchPCGuanJWaltersTDInfliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn’s diseaseInflamm Bowel Dis2014201177118624865777
   PubMed Web of Science ®Google Scholar
• HyamsJWaltersTDCrandallWSafety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extensionCurr Med Res Opin20112765166221241207
   PubMed Web of Science ®Google Scholar
• SzaboDKokonyeiGAratoAAutoregressive cross-lagged models of IMPACT-III and Pediatric Crohn’s Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn’s diseaseJ Crohns Colitis2014874775524434181
   PubMed Web of Science ®Google Scholar
• GouldthorpeOCatto-SmithAGAlexGSimpsonDLoss of response to long-term infliximab therapy in children with Crohn’s diseasePharmaceuticals (Basel)201361322133424275852
   PubMedGoogle Scholar
• GroverZBironRCarmanNLewindonPPredictors of response to infliximab in children with luminal Crohn’s diseaseJ Crohns Colitis2014873974624445015
   PubMed Web of Science ®Google Scholar
• WaltersTDKimMODensonLAIncreased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s diseaseGastroenterology201414638339124162032
   PubMed Web of Science ®Google Scholar
• LindsayJOChipperfieldRGilesAWheelerCOrchardTINDIGO Study InvestigatorsA UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn’s diseaseAliment Pharmacol Ther201338526123701393
   PubMed Web of Science ®Google Scholar
• Van AsscheGDignassAPanesJThe second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosisJ Crohns Colitis2010472721122488
   PubMed Web of Science ®Google Scholar
• RutgeertsPVan AsscheGVan DeventerSInfliximab maintenance treatment strategy results in mucosal healing in patients with Crohns diseaseGastroenterology2002122A618
   Web of Science ®Google Scholar
• D’HaensGNomanMBaertFEndoscopic healing after infliximab treatment for Crohn’s disease provides a longer time to relapseInflamm Bowel Dis20028A100
   Google Scholar
• NobileSGionchettiPRizzelloFCalabreseCCampieriMMucosal healing in pediatric Crohn’s disease after anti-TNF therapy: a long-term experience at a single centerEur J Gastroenterol Hepatol20142645846524445727
   PubMed Web of Science ®Google Scholar
• de SilvaSDevlinSPanaccioneROptimizing the safety of biologic therapy for IBDNat Rev Gastroenterol Hepatol201079310120134491
   PubMed Web of Science ®Google Scholar
• LewisJDBilkerWBBrensingerCDerenJJVaughnDJStromBLInflammatory bowel disease is not associated with an increased risk of lymphomaGastroenterology20011211080108711677199
   PubMed Web of Science ®Google Scholar
• Van AsscheGVan RanstMSciotRProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med200535336236815947080
   PubMed Web of Science ®Google Scholar
• SandbornWJFaubionWABiologics in inflammatory bowel disease: how much progress have we made ?Gut2004531366137315306602
   PubMed Web of Science ®Google Scholar
• TorunerMLoftusEVColombelJFRisk factors for opportunistic infections in inflammatory bowel diseases: a case-control studyGastroenterology200813492993618294633
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med20103621383139520393175
   PubMed Web of Science ®Google Scholar
• HouJKVelayosFTerraultNMahadevanUViral hepatitis and inflammatory bowel diseaseInflamm Bowel Dis20101692593220480515
   PubMed Web of Science ®Google Scholar
• EsteveMLorasCGonzález-HuixFLamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn’s disease patientInflamm Bowel Dis2007131450145117712837
   PubMed Web of Science ®Google Scholar
• LorasCGisbertJPMínguezMLiver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapyGut2010591340134620577000
   PubMed Web of Science ®Google Scholar
• NguyenCTTranTTHepatitis vaccination and prophylaxisClin Liver Dis20091331732919442921
   PubMed Web of Science ®Google Scholar
• SiegelCAHurCKorzenikJRGazelleGSSandsBERisks and benefits of infliximab for the treatment of Crohn’s diseaseClin Gastroenterol Hepatol200641017102416843733
   PubMed Web of Science ®Google Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med200334860160812584368
   PubMed Web of Science ®Google Scholar
• LichtensteinGRFeaganBGCohenRDSerious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™RegistryAm J Gastroenterol20121071409142222890223
   PubMed Web of Science ®Google Scholar
• ColombelJFLoftusEVJrTremaineWJThe safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patientsGastroenterology2004126193114699483
   PubMed Web of Science ®Google Scholar
• DaeHProdanovicNJaworskiJEfficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13Arthritis Rheum2013651228
   Google Scholar
• ParkWHrycajPJekaSA randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnn Rheum Dis2013721605161223687259
   PubMed Web of Science ®Google Scholar
• YooDHHrycajPMirandaPA randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnn Rheum Dis2013721613162023687260
   PubMed Web of Science ®Google Scholar
• KangYSMoonHHLeeSELimYJKangHWClinical experience of the use of CT-P13 a biosimilar to infliximab in patients with inflammatory bowel disease: a case series Available from: http://link.springer.com/article/10.1007%2Fs10620-014-3392-zAccessed April 14, 2015
   Google Scholar
• McKeageKA review of CT-P13: an infliximab biosimilarBioDrugs20142831332124723086
   PubMed Web of Science ®Google Scholar